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Introduction 30
Genomic stability is constantly susceptible to irregularities that arise from endogenous and 31 exogenous sources. One of the greatest threats to genomic integrity and implicated as a driving 32 factor in numerous diseases is oxidative stress (OS), which is defined as imbalance between 33 the production of reactive oxygen species (ROS) and antioxidant defense [1] [2] [3] DNA repair and DDR pathways. Whereas MRN complex (Mre11, Rad50, and Nbs1) as well as 45 BRCA1 and BRCA2 promote homology recombination (HR) -directed DSB repair 5-7 , Poly(ADP-46 ribose) polymerase 1 (PARP1) and X-ray repair cross-complementing protein 1 (XRCC1) have 47 been implicated in SSB repair pathway 8 . Generally speaking, DSBs trigger the activation of 48 ATM (ataxia-telangiectasia mutated) -Checkpoint kinase 2 (Chk2) DDR pathway 2,4 . On the 49 other hand, SSBs and DNA replication stress trigger the activation of ATM and Rad3-related 50 (ATR)-Checkpoint kinase 1 (Chk1) DDR pathway 9-11 . Proliferating cell nuclear antigen (PCNA) 51 coordinates the faithful and processive DNA replication and repair of the genome when needed 52 12, 13 . In addition to its critical role in ATR-Chk1 DDR pathway, TopBP1 participates in DSB repair 53 directly [14] [15] [16] [17] . Therefore, prior knowledge demonstrates that these proteins crosstalk among 54 different DNA repair and DDR pathways. 55
56
Oxidative stress-induced DNA damage is primarily repaired by base excision repair (BER) 57 pathway 2 . Oxidative DNA damage is first recognized and processed by various DNA 58 glycosylases including but not limited to MUTYH, OGG1, NTH1, and NTHL1 18 . Defects in BER 59 genes predispose to hereditary cancers. Whereas MUTYH has been established in the etiology 60 of a colorectal cancer predisposition syndrome 19 , a recent case study reports that MUTYH 61 germline and somatic aberrations are implicated in pancreatic ductal adenocarcinoma and 62 breast cancer oncogenesis 20 . OGG1 is also implicated in association with lung cancer 21 . 63 Furthermore, NTHL1 mutations or deficiencies are associated with multi-cancer phenotype 64
including colorectal cancer and breast cancer 22 . In addition, nucleotide excision repair (NER) 65 protein XPC may regulate OGG1 expression and participates in BER pathway to repair 66 oxidative DNA damage, suggesting crosstalk between different DNA repair pathways 23, 24 . 67 68 AP endonuclease 1 (APE1, also known as APEX1, Apn1, or Ref-1) and AP endonuclease 2 69 (APE2, also known as APEX2 or Apn2) have been implicated in many regulatory mechanisms 70 in the maintenance of genome stability, especially in BER pathway 8, 25, 26 . In addition to its 71 transcriptional activity of redox regulation, APE1 is the main AP endonuclease with high 72
endonuclease activity yet weak exonuclease activity to promote BER 8,25,27 . In contrast, APE2 73 has high exonuclease activity but weak endonuclease activity 11,28 . APE2 is composed of three 74 functional domains: N-terminal EEP, PCNA-interacting (PIP) motif, and a highly-conserved C-75
terminal zinc finger Zf-GRF 10 . APE2 interacts with PCNA via two different modes, promoting 3'-76 5' SSB end resection for the activation of ATR-Chk1 DDR pathway 9-11 . Accumulating evidence 77 has suggested that abnormal expression of APE1 is implicated in cancer such as gastric cancer 78 and ovarian cancer [29] [30] [31] . Both APE1 and APE2 have previously been found to be upregulated in 79 multiple myeloma cell lines 32 . However, it remains unknown whether the expression of APE2 in 80 patient-derived tumor tissues is altered when compared with non-malignant tissues across 81 multiple cancer types. 82
83
When genetic irregularities arise within DNA repair and DDR mechanisms, OS-induced damage 84 may not be properly repaired, leading to genome instability and compromised protein production 85 2,3,33 . Copy number variations (CNVs), point mutations, and irregular gene expression patterns 86 are examples of genomic alterations that have the potential to impact protein structure and 87 function. Here, we conduct a multi-cancer bioinformatics analysis of APE2 at DNA, mRNA, and 88 protein levels from publicly available data across multiple studies and cancer tissue types. In 89 this study, we examine genomic alterations (somatic mutations and CNVs) occurring in APE2 in 90 vivo from 14 cancer types and if APE2 is differentially expressed in 6 types of tumor tissue 91 compared with non-malignant tissue. Furthermore, we analyze mRNA expression between 92 APE2 and 13 critical DNA repair and DDR proteins. To the best of our knowledge, this work is 93 the first to provide patient-derived evidence showing that abnormal expression of APE2 is 94 implicated in multiple cancer types and that APE2 expression is correlated with the expression 95 of various DNA repair and DDR proteins. We also discuss the function and biology of APE2 in 96 genome integrity. 97 98 Methods 99
Data sets 100
Multiple-study data for genomic alteration events in 14 different cancer types was retrieved from 101 the cBioPortal for Cancer Genomics. Although the cBio repository contains data for 30 different 102 primary sites, only data for these 14 cancer types adhered to the following criteria at the time of where matched tumor and non-malignant tissue data was available for each individual was the 114 determining factor by which cancer types were chosen for gene expression analysis. See 115
Discussion for more information on an exception made to this criteria. Tissue samples for gene 116 expression quantification data were originally obtained from patients at tissue source sites 34 117 such as Columbia University, Mayo Clinic, Duke University, and the University of Pittsburgh. 118
Tissue samples were then sent to one of two biospecimen collection sites (BCRs) where RNA 119 was isolated, clinical data standardized, and analyte distribution conducted. Samples and 120 associated data were then sent to a genome characterization or sequencing center (GCC or 121 GSC, respectively) where data was sequenced with Illumina HiSeq technologies. For gene 122 expression quantification, mRNA transcripts were aligned and the .bam files quantified with 123
HTSeq. Read count data from HTSeq and from STAR are available, as well as fragments per 124 kilobase of transcript per million mapped reads' (FPKM) and FPKM-UQ normalized data. Read 125 count data is often used for global differential expression analysis of gene sets. FPKM 126 normalization method is much more specific, taking into consideration of gene length 127 differences and is often a preferred method for gene-gene expression comparisons 35 . Since we 128 focus on single gene and gene-gene pair analysis in this study, we use the FPKM normalized 129 data where read count is divided by gene length. 130 131
Data pre-processing 132
Genomic alteration event files containing information on APE2 per cancer type were 133 downloaded from cBioPortal website in TSV format. Files were then programmatically parsed 134 for relevant information from tumor tissue samples, removing duplicate data and any individuals 135 for whom alteration event data was either not available or not explored. To reduce redundancy, 136 only the first record for tumor tissue samples with more than one record was included in 137 analyses. 138
139
File pre-processing for mRNA gene expression quantification included renaming files from UUID 140 to the associated TCGA barcode. Two new sets of files were created after parsing original files: 141 one set contained data for all tumor data for APE2 and 13 additional genes implicated in DDR 142 pathways, one set contained only expression data from individuals for whom both tumor and 143 matched non-malignant tissue samples were available. Table S3 shows sample sizes for tumor-144 only tissue and matched tissues per cancer type in our analysis. 145
146

Genomic alteration event analysis 147
To characterize the frequency of genomic alteration events in APE2, the frequency of each 148 event type per cancer type was calculated in Excel and plotted in R. Genomic alteration plots 149 were created in R and figures representing APE2 protein domains and mutations -along with 150 R-generated plots -were created in PowerPoint. 
Bioinformatics tools 160
Data from the GDC portal was downloaded using the provided transfer tool. For pre-processing 161 of data, scripts written in Python, utilizing the os.walk module, were used to parse, create, and 162 rename files. To find matching TCGA barcode per UUID, UUIDtoBarcode from the R-package 163
TCGAUtils was used 36 . From R-package ggplot2 and dependencies, genomic alteration 164 frequency plot and somatic mutation plots were created using ggplot and scatterplots created 165 with ggscatter 37 . All R-packages were implemented, and statistical analyses and plots were 166 Results 170
Genomic alterations in APE2 across all cancer types 171
To verify the occurrence of APE2-situated genomic alterations in cancer patients, data from 14 172 cancer-types in the cBiolPortal database was programmatically analyzed. From all samples for 173 which data were available and had been evaluated for genomic alterations (n=21,769), genomic 174 alterations in APE2 occurred at ~17% frequency and appeared in each cancer type ( Fig. 1) . 175
Cancers with the highest frequency of total events were skin (24.35%), liver (23.88%), and 176 breast (23.72%) ( Fig. 1 , Table S1 ). From the total alteration events observed, heterozygous 177 deletions occurred most frequently (51.18%), gains next (40.77%), then amplifications (3.77%) 178 and mutations (3.11%) with homozygous deletions occurring at the lowest frequency (1.17%). 179
CNVs in APE2 were found at varying levels across each cancer type. Gains occurred most 180 frequently in lymphoid cancer (14.30%), amplifications most often in prostate cancer (3.28%), 181 heterozygous deletions observed most frequently in liver tumor tissue (15.42%), and head and 182 neck cancerous samples revealed the highest frequency of homozygous deletions (1.07%) ( Fig.  183 1, Table S1 ). Frequency of somatic mutations in APE2 ranged from 2.89% (uterus) to 0.10% 184 (head and neck), although its somatic mutations did not appear in kidney nor pancreas tumor 185 tissue. 186 187
Occurrences of coding truncations and amino acid changes in APE2 188
In addition to the analysis of APE2 genomic alterations, protein consequences of somatic 189 mutations in APE2 were analyzed. Protein-level annotations of somatic mutations in APE2 were 190 extracted from genomic alteration event data for 12 cancer types (Table S2) . A total of 117 191 mutations were found in APE2 with uterine (40), lung (22), and skin (16) tumor tissue revealing 192 the highest number of mutations ( Fig. 2A , Table S2 ). Mutation events were comprised mainly of 193 missense mutations with several nonsense mutations which create premature stop codons, 194 frameshift deletions which are deletions of chunks of protein sequence that create a shift in 195 remaining amino acids, and alternative splices denoted with an 'X' indicating a translation 196 termination codon at the site ( Fig. 2A-2C ). Tumor tissues with the highest frequency of somatic 197 mutations in APE2 were uterus (2.89% = 40 out of 1,386), skin (2.47% = 16 out of 649) and lung 198 (0.78% = 22 out of 2,831) tumor samples ( Fig. 2B ). Notably, out of the 117 mutations, 29 199
Arginine residues (~25%) were mutated to other residues, suggesting a distinct feature of APE2 200 missense mutations ( Fig. 2A-2B , Table S2 ). The Arginine residue at position 465 was mutated 201
to Histidine (i.e., R465H) in skin and cervical tumor samples, and to Cysteine (i.e., R465C) in 202 more than one individual with uterine cancer. An Arginine to Cysteine mutation was found at 203 position 173 (i.e., R173C) in one breast cancer and two uterine tumor samples. A R222C and a 204 R222H mutations were found in uterine cancer, and the R222C mutation was also found in a 205 brain cancer sample. 206
Additionally, four nonsense mutations of APE2 were found in lung cancers (Q235*, Q380*, and 207 E448*) and uterine cancer (E444*) creating premature stop codons ( Fig. 2C ). Of the two 208 frameshift deletions found, one was in uterine tissue (T356Cfs*37) and one in lung cancer 209 (L464Cfs*14) ( Fig. 2C ). Furthermore, three alternative splices were revealed in uterus (X141, 210 X190) and skin cancers (X214) (Fig. 2C) . 211 212
Upregulation of APE2 mRNA expression in tumor tissue 213
After establishing the occurrence of alterations in APE2 at the genomic level, APE2 expression 214 at the mRNA level was analyzed. To find if APE2 is differentially expressed in cancer patients, 215 gene expression quantification data was computationally compared between tumor and non-216 malignant tissue using a two-sided t-test in R. Samples referred to as 'matched' indicate 217 individuals where non-malignant and tumor tissue were both available in the data (Table S3 and 218 Table S4 ). FPKM (fragments per kilobase of exon model per million reads mapped) values of 219 mRNA sequencing data for APE2 in matched samples revealed significant upregulation (α = 220
.05) in tumor tissue compared with non-malignant tissues across 5 cancer types including 221 kidney (n = 126), breast (n = 112), lung (n = 106), liver (n = 58), and uterine (n = 23) cancers 222 ( Fig. 3A-3D, 3F ). Matched samples from prostate cancer patients (n = 52) did not present a 223 significant difference in APE2 FPKM values (Fig. 3E) . 224
225
To establish a baseline for finding correlations -between expression patterns in APE2 and 13 226 other DNA repair and DDR pathway genes -in tumor tissue, matched samples were further 227 analyzed for differential expression in these genes. Notably, in most, if not all, cancer types 228 analyzed, mRNA expression of 11 out of the 13 DNA repair and DDR genes are upregulated in 229
tumor tissue compared with that in non-malignant tissue. Analysis of these genes revealed 230 significant upregulation in APE1, BRCA1, Chk1, Chk2, and TopBP1 for all cancer types ( Fig.  231 S1-S5). Like APE2, PCNA, BRCA2 and XRCC1 were also significantly upregulated in all cancer 232 types except prostate ( Fig. S6-S8 ). PARP1 was upregulated in all cancer types except kidney 233 cancer ( Fig. S9 ). mRNA expression of ATR in tumor tissue was increased compared with 234 matched non-malignant tissue in liver, lung, uterus, and prostate cancers, but not in breast and 235 kidney cancers (Fig. S10 ). Rad50 mRNA expression was upregulated in almost all cancer types 236 except uterine cancer (Fig. S11) . 237 238 Intriguingly, mRNA expression of ATM and Mre11 was upregulated in tumor tissue compared 239 with matched samples in some cancer types but downregulated in other cancer types ( Fig. S12 -240 S13). ATM expression was upregulated in kidney and liver cancers, but not in lung and prostate 241 cancers, while it was downregulated in breast and uterine cancers (Fig. S12 ). Mre11 expression 242 was upregulated in lung and liver cancers, but not in kidney, prostate, and uterus cancers, and 243 was significantly downregulated in breast cancer (Fig. S13) . 244 245
Patterns in mRNA expression between APE2 and other DNA repair and DDR genes 246
Because co-expression and interactive partners of APE2 are not yet well known, it is significant 247 to compare expression levels of APE2 to other DNA repair and DDR genes. After establishing 248 differential expression patterns for reach gene per cancer types, FPKM values of APE2 were 249 correlated with 13 other DNA repair and DDR genes in tumor tissue only for breast (n= 1,105), 250 lung (n= 1,028), kidney (n= 891), uterine (n= 552), prostate (n= 499), and liver (n= 407) cancers 251 (Table S3 and S5). While APE2 had a significant (α = 0.05) positive correlation with PCNA, 252 APE1, XRCC1, PARP1, Chk1, and Chk2 across all 6 cancer types, groupings of DNA repair 253 and DDR genes were found to be correlated with APE2 in different patterns in different cancer 254 types ( Fig. 4, and Fig. S14-S18 ). In liver cancer, correlations of APE2 with these 13 DNA repair 255 and DDR genes were all positive ( Fig. S14) . Out of the 13 other genes, 11 had the significantly 256 strongest relationship per gene with APE2 in liver cancer (determined by R-value and α = 0.05) 257 and gene-gene pair. The positive correlation between the expression of APE2 and PCNA was 264 most significant in prostate cancer. However, neither APE2 nor PCNA expression values was 265 significantly different in matched prostate tumor ( Fig. 3E and Fig. S6E ), thus there is no baseline 266 to strengthen the implications of this APE2-PCNA correlation. Weak APE2-APE1 expression 267 correlations were observed in lung and kidney cancers, which is consistent with the significant 268 role of APE1 and APE2 in SSB repair 11, 42, 43 . When APE2 and PARP1 values were correlated, 269 liver and uterine cancer samples showed more variability whereas very little spread occurred in of Chk1 and Chk2 in all 6 cancer types (breast, liver, prostate, uterine, lung, and kidney) ( Fig. 4,  276 Fig. S14-S18). It is noted that the strongest positive correlation of APE2 with Chk1 and Chk2 is 277 found in lung cancer (Fig. S17) . 278
279
BRCA1 and BRCA2 280
When APE2 expression was correlated with expression of BRCA1 and BRCA2, the top 4 281 strongest positive correlations were, in order starting with strongest, liver, lung, prostate, and 282 uterus. Whereas there were no significant correlations of APE2 to BRCA1 and BRCA2 in breast 283 cancer ( Fig. 4) , kidney cancer samples exhibited a negative correlation of APE2-BRCA2 and a 284 positive correlation of APE2-BRCA1 ( Fig. S18, and Table S5 ). 285 286
TopBP1 and ATR 287
The APE2-ATR relationship was positive in liver and lung cancer but negative in breast cancer. 288 Furthermore, the APE2-ATR correlation was not significant in prostate, uterine, nor kidney 289 cancers. Although a positive correlation of APE2-TopBP1 was revealed in liver, prostate, uterus, 290 and lung cancers, the APE2-TopBP1 correlation was not significant in kidney nor breast cancer. 291
292
ATM, Mre11, and Rad50 293
The APE2-ATM correlation was negative in all cancer types expect liver. APE2 did not have a 294 significant relationship with Mre11 or Rad50 in uterine nor prostate cancers. The correlation of 295 APE2 with Mre11 was positive in liver and lung cancers, and negative in breast and kidney 296 cancers. In addition, the APE2-Rad50 correlation was negative in breast, kidney, and lung 297
cancers, yet positive in liver cancer. 298
Discussion 299
Function and biology of APE2 300
The human APE2 gene was first cloned and briefly characterized in 2000 44 . However, the 301 understanding of APE2 in DNA repair and DDR pathways has been derived from studies of 302 model organisms such as Xenopus and yeast 9-11,45-49 , despite some biochemical and sub-303 cellular localization characterization of human APE2 protein 28,50,51 . Recent genetic screens 304 identified APE2 as a synthetic lethal target in BRCA1-and BRCA2-deficient colonic and ovarian 305 cancer cell lines 52 . Although the exact underlying mechanism remains unknown, this report 306 suggests that APE2 may contribute to different DNA repair pathways other than BRCA1-and 307 BRCA2-mediated DSB repair. Consistent with this, our series of studies using Xenopus egg 308 extract system suggest that APE2 plays a direct role in SSB repair via the 3'-5' SSB end 309 resection 11,26,43 . Of note, gene expression of APE2 and APE1 has been found up-regulated in 310 multiple myeloma (MM) patients and MM cells, which may lead to dysregulation of HR via 311 regulating Rad51 expression 32 . These new evidences suggest that APE2 contributes to 312 genome integrity via different mechanisms. 313
314
A prior study has shown that APE2-knock out (KO) mice are viable but develop immune 315 response defects and growth retardation 53 . Subsequent characterization of APE2-KO mice 316 revealed the significance of APE2 in B cell development and immunoglobulin class switch 317 recombination 54,55 . Interestingly, recent evidences suggest that ATR and BER pathways are 318 involved in regulating the expression of Programmed death-ligand 1 (PD-L1), an important 319 player for immunotherapy [56] [57] [58] . As APE2 has been shown in both BER and ATR pathways 11,50 , 320
it is interesting to test whether APE2 is directly involved in cancer immunotherapy in future 321
studies. 322
Due to the lack of in-dept knowledge about APE2 functions in human diseases, the purpose of 324 this study has been to contribute knowledge from such an angle to investigate the genomic 325 alterations and abnormal expression of APE2 in human cancers. Using data from samples 326 across multiple cancer types has been advantageous in providing a snapshot of APE2 327 characteristics in cancer yet there are limitations which must also be acknowledged. 328
329
Genomic alterations and abnormal expression of APE2 in cancer samples 330
Our data from 21,769 cancer patients revealed that genomic alterations of APE2 occur with 331 approximately 17% frequency across all cancer types (10.54% in pancreas -24.35% in skin). 332
This observation suggests the potential involvement of APE2 in cancer development, although 333 future studies are needed to test this question directly. Frequencies of CNVs in APE2 for gains, 334 amplifications, heterozygous deletions, and homozygous deletions vary significantly per cancer 335 type. For example, the frequencies of APE2 gain (8.94%), amplifications (0.31%), heterozygous 336 deletions (12.63%), and homozygous deletions (0%) from 1,386 skin cancer patients are 337 different from those frequencies in other cancer types. In some cancers, such as breast and 338 liver, heterozygous deletions are the most frequent CNV type. Alternatively, for lymphoid, 339 uterine, and prostate cancer, gains occur most frequently. 340
341
In addition, Arginine mutations dominating APE2 somatic mutations are a distinct feature. In 342 particular, there are 8 Arginine mutations localized in the extreme C-terminus Zf-GRF motif of 343 APE2 (i.e., R465C, R465H, R490H, R491C, R497S, R499W, R508Q, R516M). Our previous 344 studies have shown that R473A, R473E, R502A, and R502E mutant APE2 in Xenopus 345 (homologous to R479 and R508 mutants in human APE2) is deficient in ssDNA binding 10 , and 346 that G483A-R484A double mutants of Xenopus APE2 (homologous to G489A-R490A double 347 mutants in human APE2) are defective for ssDNA binding and PCNA interaction 11 . We 348 speculate that the Arginine missense mutations in human APE2 identified from this study may 349 compromise its ssDNA binding and/or PCNA interaction, leading to compromised exonuclease 350 activity and associated genome instability. 351
352
Our results on APE2 mRNA expression from matched tumor and non-malignant tissue 353 demonstrate its overexpression in kidney, breast, lung, liver, and uterine cancers, but not in 354 prostate cancer (Fig. 3 ). This pattern of APE2 overexpression is also found in PCNA, BRCA2, 355 and XRCC1 ( Fig. S6-S8 APE2 to regulate its exonuclease activity 11, 28, 45, 47, 50 . A recent genetic screen has revealed that 359 APE2 is a synthetic lethal target in BRCA2-deficient cells 52 . Although APE2 and XRCC1 are 360 involved in BER pathway, it seems that they contribute to SSB repair via different mechanisms 361 43 . 362
363
A prior study revealed that mRNA expression of APE1 and PARP1 is upregulated in tumor 364 tissue compared with that in non-malignant tissues from 53 paired colorectal cancer patients 59 . 365 This is consistent with our observation of upregulation of APE1 mRNA in kidney, breast, lung, 366 liver, prostate and uterus cancers (Fig. S1 ), and increased PARP1 mRNA expression in breast, 367 lung, liver, prostate and uterus cancers (Fig. S9) . Although upregulation or downregulation of 368 individual genes in the BER pathway is often found in tumor tissue over non-malignant tissue, 369 overall BER capacity has been proposed a determinant of prognosis and therapy response to 370 DNA-damaging 5-fluorouracial in colon cancer patients 60 . 371 372
Correlation of APE2 mRNA expression with other DNA repair and DDR proteins 373
We have shown that APE2 expression is positively correlated with the expression of PCNA, 374 APE1, PARP1, XRCC1, Chk1, and Chk2 across all six cancer types analyzed in this work ( Fig.  375 4, Fig. S14-S18 ). This may be interpreted that APE2 is involved in BER and SSB repair 376 pathways as same as PCNA, APE1, XRCC1, and PARP1 11,28,42,43 . Recent studies showing the 377 role of APE2 in Chk1 phosphorylation in oxidative stress could provide feasible explanation for 378 the positive correlation found between APE2 and Chk1 9,10 . Interestingly, APE2 expression is 379 negatively correlated with ATM expression in all cancer types except liver cancer, suggesting 380 that APE2 and ATM may be in different DDR pathways. 381 382 Due to tumor heterogeneity, there is no 'one-size-fits-all' formula that can be applied to the 383 prediction, prevention, or therapy of cancer or other human diseases. In this study we 384 demonstrate the varying gene expression and genomic alteration profiles of APE2 by tissue site 385 and even by individual in multiple cancers. Future studies that include more tissue sites, 386 additional metadata, and consider other potential molecular partners of APE2 will be useful in 387 establishing the genomic landscape in which certain APE2 characteristics can be implicated as 388 predictive markers or therapeutic targets. 389 390
Consideration of sample sizes 391
The presence of matched samples in TCGA dataset provides clear indication of whether APE2 392 changes in tumor tissue per individual, yet many of the cancer type sample sizes of matched 393 tissues in TCGA were too small to provide statistical value. Due to the prevalence of some 394 cancer types over others, it is infeasible to obtain consistently large quantities of data for all 395 cancer types. Furthermore, some tumor tissue samples are available in 'study-worthy' amounts, 396 yet the collection of matched non-malignant tissues is not available due to the nature of the 397 tissue. For instance, brain cancer datasets contain little to no matched non-malignant samples 398 because extraction of non-malignant tissue from a living human brain could have detrimental 399 effects on the individual. Additionally, tumor location and size can impact the availability of non-400 malignant tissue. If the affected organ is already small or the tumor has spread to the entire 401 organ, insufficient amounts of non-malignant tissue would be left for extraction or analysis. 402 403
Consideration of data availability 404
Gene expression quantification data was useful in understanding the transcriptome surrounding 405 APE2. In this study, data from multiple cancer types reveals not only APE2 characteristics in 406 disease but suggests tissue-dependent or tissue-specific characteristics. All available data from 407 TCGA has been subject to uniform protocol and strict quality control, indications of valid and 408 consistent datasets. However, data from certain cancer studies could not be used in this version 409 of TCGA data due to discrepancies. For example, bladder and colon cancer datasets contained 410 identical gene expression quantification data and thus, due to lack of clarity, were not included 411 in the current study. Protein expression data from The Cancer Proteome Atlas (TCPA) is 412 available for many of the same individuals in the TCGA datasets we have analyzed here. An 413 analysis of matched protein expression could be duly advantageous for examining APE2 414 transcription levels to the level of expressed protein and to compare translation of APE2 with 415 other DNA repair and DDR genes. Regardless, APE2 is not included in the TCGA/TCPA protein 416 quantification analyses, deeming the protein expression data inefficient for the current study. 417 418 Downloadable files of somatic mutation data from cBio contained conflicting information from 419 that which could be visualized on the web interface of cBioPortal. For example, somatic 420 mutations A372T and G462E found in skin cancer were not included in the files but do appear 421 on the cBioPortal website. These missing mutations were found and manually added to 422 analyses. Likewise, genomic alteration data from cBio is missing for a large number of samples, 423 resulting in slightly less robust results. Furthermore, ploidy and purity of copy number calls could 424 be different across studies. Due to a general lack of prior manual review that could ensure 425 uniform quality of data available from cBioPortal, the CNV data has the potential to represent a 426 number of false positives and false negatives (docs.cbiopotal.org). Despite minor limitations with 427 sample sizes and lack of availability for particular data-types, we believe the magnitude and 428 overall quality of data analyzed here has been sufficient to capture certain patient-derived 429 characteristics of APE2 in disease. counted. 628
